Aktuellt
SENASTE
Redeye comments on Scandion Oncology’s Q2 2023 report, and we judge that CORIST part 4 data in 2024e is the primary catalyst for the company’s share in the coming 12-18 months. Further, we believe CORIST part 3 top-line data in H2 2023e and more granular PANTAX data in Q4 2023e-H1 2024e might provide minor catalysts. We do some housekeeping in our model.
LÄS MER
